Summary & Overview
HCPCS J0222: Injection, patisiran, 0.1 mg
HCPCS Level II code J0222 denotes the injectable biologic patisiran measured per 0.1 mg. Patisiran is a therapy used for hereditary transthyretin-mediated amyloidosis and related clinical indications; accurate reporting with J0222 supports clinical documentation, drug utilization tracking, and payer processing for high-cost specialty pharmaceuticals. Nationally, clear use of this HCPCS Level II code matters because specialty infusions drive significant outpatient drug spending and require consistent coding to align clinical intent, benefit eligibility, and medical necessity review.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact briefing on what J0222 represents, typical sites where the service is delivered, and the practical implications for billing workflows. The publication summarizes reimbursement benchmarks, payer policy considerations, and coding nuances tied to injectable specialty therapies. Clinicians and billing professionals will gain a concise reference for documentation expectations, claim submission context, and topics to monitor such as policy updates and coverage criteria. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0222 represents the injection of patisiran, 0.1 mg. This billing code documents administration of the therapeutic agent patisiran, a small interfering RNA indicated for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy and related indications.
-
Service type: Intravenous or parenteral drug administration (injectable biologic)
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hereditary transthyretin-mediated amyloidosis (hATTR) presenting with progressive peripheral neuropathy and/or cardiomyopathy who is prescribed patisiran therapy. The patient undergoes baseline evaluation including neurologic exam, ambulatory status assessment, laboratory studies (CBC, CMP), and documentation of weight for dose calculation. Treatment is administered as an intravenous infusion in an outpatient infusion center, specialty clinic, or hospital outpatient department by an infusion nurse under the supervision of a neurologist, cardiologist, or a hematology/oncology specialist experienced with biologic therapies. Prior to each infusion, premedication orders (antipyretic, antihistamine, corticosteroid as indicated) are reviewed and any prior adverse infusion reactions are reconciled. The patient’s vascular access is established via peripheral IV or existing central access; patisiran is prepared by pharmacy in an appropriate diluent and administered per manufacturer infusion time and monitoring guidelines. During and after infusion, the patient is observed for infusion-related reactions and vitals are documented. Follow-up includes monitoring for efficacy (neurologic and cardiac function as appropriate), routine labs, and documentation of each billed unit of J0222 (each unit = 0.1 mg) matched to the administered mg dose and supporting clinical notes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|